The molecular genetics of panic disorder (PD) with and without agoraphobia (AG) are still largely unknown and progress is hampered by small sample sizes. We therefore performed a genome-wide association study with a dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia Cognition Questionnaire (ACQ) in a sample of 1370 healthy German volunteers of the CRC TRR58 MEGA study wave 1. A genome-wide significant association was found between ACQ and single non-coding nucleotide variants of the GLRB gene (rs78726293, P = 3.3 × 10
Cognitions Questionnaire (ACQ). 5 Family studies reveal familial aggregation in PD and AG 6, 7 and twin studies estimated heritabilities of about 38% and 48%, with a genetic correlation of 0.83 between both disorders. 8 Linkage and candidate gene association studies of PD/AG were mostly negative or inconsistent [9] [10] [11] [12] because of phenotypic diversity, genetic heterogeneity and underpowered sample sizes. Of the candidate genes, only the catechol-O-methyltransferase (COMT) [13] [14] [15] gene, the neuropeptide S receptor gene (NPSR1) 16 and the monoamine oxidase A (MAOA) gene [17] [18] [19] have been implicated in susceptibility to PD by several independent studies and meta-analyses within the European population. 11, 12, 20, 21 Two genome-wide association studies (GWAS) on PD/AG [22] [23] [24] [25] have been published. In contrast to the more advanced GWAS, for example, in schizophrenia, 26 GWAS in PD are characterized by small sample sizes (hundreds versus thousands). However, the TMEM132D gene identified in a GWAS was confirmed in the European population in an independent meta-analysis. 11 An alternative approach utilized were GWAS studies on dimensional traits (neuroticism and phobic anxiety), [27] [28] [29] which supported a locus on chromosome 1, but so far showed inconclusive results with regard to individual genes. Recently, an approach studying anxiety disorders combined and quantitative phenotypic scores was applied providing genome-wide evidence for a non-coding RNA locus on chromosome 3q12.3 and the CAMKMT (calmodulinlysine N-methyltransferase) gene on chromosome 2p21. 30, 31 Assuming a dimension from agoraphobic cognitions to full PD/AG, we (1) conducted a GWAS on a dimensional anxiety phenotype (ACQ) in a sample of 1370 healthy German volunteers to generate hypotheses for further investigations. We then (2) evaluated the GLRB locus in a larger dimensional ACQ sample, comprising 2547 healthy volunteers. Next, we validated our findings (3) in a Dutch control sample (N = 3845) with a dichotomous measure of AG symptoms (Symptoms Checklist-90 (SCL-90)) and (4) assessed the relevance of the association for the categorical phenotype PD/AG by analyzing 506 case-control pairs. To probe molecular consequences of GLRB genetic variation, we (5) measured mRNA expression in vitro and post mortem. As singlenucleotide mutations in GLRB underlie hyperekplexia 2 (OMIN #614619), characterized by exaggerated startle response, we examined the effect of the identified GLRB risk polymorphisms on startle habituation (6) , potentiation (7) and generalization (8) . This was complemented by (9) functional magnetic resonance imaging (fMRI) analysis of fear network and general sensory activation. Finally (10), we performed an analysis of agoraphobic behavior in mice with a partial Glrb knockout.
MATERIALS AND METHODS

GLRB locus, agoraphobic cognitions and PD/AG
Samples. To identify loci associated with agoraphobic traits as defined by the ACQ 5 (German version   32 ), we examined 1370 healthy German volunteers by conducting a GWAS and then evaluated the genome-wide significant locus in a larger sample comprising 2547 German healthy controls (MEGA study waves 1 and 2). 33, 34 We validated the locus in 3845 independent Dutch participants of the Nijmegen Biomedical Study (NBS) 35 for a dichotomous SCL-90 36, 37 (Dutch version   38 ) based agoraphobic cognitions phenotype and at the categorical level by comparing 506 PD patients (PanicNet study waves 1 and 2) 16, 19, 21, 39, 40 with 506 matched controls from MEGA study waves 1 and 2. In all but the NBS studies, PD/AG patients and probands with severe psychiatric, neurological or somatic disorders, as well as drug and alcohol abuse were excluded. Only individuals with written informed consent were enrolled, which complied with the Declaration of Helsinki and was approved by the respective local ethics committee. For a demographic overview, see Supplementary  Table 1 .
Genotyping. Participants of the MEGA wave 1 sample were genotyped on Illumina's Human-Hap550v3 BeadChips using the Infinium II assay (Illumina, San Diego, CA, USA) at the Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany. Quality control procedures were performed as described previously 41 with slightly modified exclusion criteria: single-nucleotide polymorphisms (SNPs) and subjects with call rates (CRs) ⩽ 99%; minor allele frequency ⩽ 1%; failing Hardy-Weinberg equilibrium (Po 10 − 5 ); principal component analysis 44-fold s.d. of the first three principal components. To increase genomic coverage, imputation was conducted using MACH v1.0.18.c/MINIMACH v2013-07-17 (refs 42,43) and the 1000 Genomes reference data set. 44 Post-imputation quality control includes: SNPs and subjects CR ⩾ 95%, minor allele frequency ⩾ 1%, failing Hardy-Weinberg equilibrium (P ⩾ 10
), imputation quality score o0.3, population stratification, gender and unreported relatedness check. The GWAS was free from genomic inflation in the quantile-quantile plot (λ = 1.000933) as shown in Supplementary Figure 1 .
NBS was genotyped using the Illumina Human Omniexpress-12 and -24 chip. The pre-imputation quality control steps applied to the NBS cohort include: SNP minor allele frequency 41%, Hardy-Weinberg equilibrium 410 − 4 , SNP yield and individual CR495%. Imputation was done using IMPUTE v2.3.0 following the BBMRI-NL pipeline (http://www.bbmriwiki.nl/ wiki/Impute2Pipeline) using the 1000 genomes phase 1 v3 and GoNL reference panels combined. Post-imputation quality control comprised a gender check, unreported relatedness between participants and population stratification.
For fine mapping, we captured GLRB and its flanking regions (+40/ − 10-kb upstream/downstream) by 21 tagSNPs derived from dbSNP European data (http://manticore.niehs.nih.gov/snpinfo/snptag.htm). Genotyping was performed using the Sequenom MassArray system (Sequenom, San Diego, CA, USA; for primer sequences see Supplementary Table 2 ) and for rs17035628 using a 'KASP on demand' assay (LGC Genomics, Hertfordshire, UK) as recommended by the manufacturers. After quality control, the final data set included 20 (2 GWAS SNPs+18 tagSNPs) markers with a minor allele frequency ⩾ 1%, CR ⩾ 90% and Hardy-Weinberg equilibrium (controls only) P ⩾ 0.01; rs17035590, rs17035814 and rs17035628 had to be excluded.
For details on statistical and power analysis see Supplementary Methods.
Functional assessment: bioinformatic, post-mortem and cell system expression analyses To detect functional variation on expression of GLRB and neighbor genes, we analyzed our strongly associated variants, using the GTEx eQTL database (http://www.gtexportal.org/home).
For expression analysis of the promotor SNP rs7688285, post-mortem brain samples of 76 individuals (mean age 48.6 ± 12.8) were obtained from the Medical Research Council (MRC) Sudden Death Brain and Tissue Bank, Edinburgh, UK. Detailed information on the sample and mRNA quantification are described elsewhere. 45 Allele-specific changes of rs7688285 on mRNA expression were calculated by linear regression with genotype and sample RNA Integrity Number as independent and expression values as dependent variable according to a dominant model.
For expression analysis in a heterologous cell system, 20-bp flanking rs7688285 up-and downstream were subcloned into pGL4.23 vector for both alleles, allowing expression of firefly luciferase under the control of a minimal promotor. For details, see Supplementary Methods.
Functional assessment: startle reflex
Samples. Participants of MEGA and PanicNet waves 1, who had taken part in various assessments of defensive behavior, 33, 46, 47 were studied regarding the effect of GLRB variation on startle reflex modulation. Individuals carrying at least one GLRB risk allele (that is, those highly significantly associated with either ACQ or PD, namely: rs78726293 (A allele), rs191260602 (G allele), rs17035816 (G allele) or rs7688285 (A allele)) were classified as 'risk allele carriers'. Accordingly, of 101 healthy volunteers who participated in an emotion-potentiated startle paradigm 24, of 76 healthy volunteers who participated in a context-conditioning paradigm 23 and of 115 PD/AG patients who participated in a behavioral avoidance test 52 were risk allele carriers. For sample characteristics and genotype counts, see Supplementary Table 3 .
Paradigms. Startle reactivity was investigated in three paradigms selected to allow for hierarchical analysis of startle reactivity with increasing complexity, focusing on (a) startle habituation during an emotion-potentiated startle paradigm, 33 (b) startle potentiation triggered by a threatening environment during the behavioral avoidance test 47 and (c) startle generalization during context conditioning. 46 For a detailed description on startle methodology, paradigms and statistical analyses see Supplementary Methods.
Functional assessment: fear network
Sample. Healthy volunteers from two studies (study 1: N = 72; 48 study 2: N = 38) with identical experimental design during a cue fear-conditioning paradigm were included. All participants were right handed with normal or corrected-to-normal vision. All participants were recruited from the MEGA study wave 2. Participants were grouped into risk and no-risk allele carriers as described above (risk: N = 33). For sample characteristics, see Supplementary Table 3 .
Experimental design. Two visual stimuli served as conditioned stimuli (CSs) and three electro-tactile stimuli as unconditioned stimuli. The CS+ was always, and the CS-never was followed by the unconditioned stimuli, whereas skin conductance responses, fear ratings and fMRI data, were acquired (see 48, 49) .
All behavioral data (skin conductance response and ratings) were analyzed using SPSS 22 for Windows (IBM, Armonk, NY, USA) using repeated-measures analyses for CS type per experimental phase (first half acquisition, second half acquisition and extinction). Rating values after fear acquisition were corrected for pre-acquisition scores. An α-level of P o0.05 was considered significant (unless otherwise stated), and GreenhouseGeisser corrected degrees of freedom were used when appropriate. For a detailed description on fMRI data acquisition, preprocessing and statistical analyses see Supplementary Methods.
Agoraphobic behavior in heterozygous Glrb knockout mice
Animals. The spastic mouse 50, 51 has an insertion of a LINE1 element into intron 5, resulting in lower expression levels of the full-length glycine receptor beta (Glrb spa ). Heterozygous Glrb +/spa do not show the spastic phenotype. All experiments were done with adult C57BL/6J and C57BL/6J Glrb +/spa mice (Jackson Laboratories, Bar Harbor, ME, USA) in accordance 
Open field test
Wild-type and heterozygous Glrb +/spa mice were tested individually for anxiety-like behavior. They were placed in a 48 × 48 cm square box, illuminated with~40 lux. Animals were monitored for 10 or 30 min each and tracked with the Video Mot Software (TSE Systems, Bad Homburg, Germany). For analysis, the box was divided into fields of interest: center of the arena (24 × 24 cm) versus the periphery. The first 5 min were analyzed counting entries and time spent in center. 52 Differences between genotypes were tested using a two-way analysis of variance with Bonferroni posttest or an unpaired t-test.
RESULTS
GLRB locus, agoraphobic cognitions and PD/AG After quality control of post-imputational data, altogether 1370 healthy volunteers from MEGA wave 1 with information of 7 071 105 autosomal markers were available for analysis. GWAS analysis on ACQ yielded 122 markers with P o1 Table 5 ). On chromosome 4, genome-wide significance was reached for the imputed SNPs rs78726293 (P = 3.3 × 10 − 8 ; imputation quality score = 0.58) and rs191260602 (P = 3.9 × 10 − 8 ; imputation quality score = 0.68), both located in an intronic region of the glycine receptor beta (GLRB) gene. This locus was supported by a nearly genome-wide signal, rs115177500 (P = 8. Both genome-wide significant polymorphisms rs78726293 and rs191260602 and further 18 SNPs fully tagging GLRB were genotyped and analyzed in a larger ACQ sample (MEGA waves 1 and 2; N = 2547; Table 1 ). The genome-wide significant SNPs, rs78726293 and rs191260602, and in addition rs17035816 were strongly associated in the larger sample (P rs78726293 = 4.3 × 10 − 4 ; P rs191260602 = 8.8 × 10 − 5 ; P rs17035816 = 3.8 × 10 − 4 ), always with the minor allele increasing ACQ sum scores (Table 1) .
All 20 examined SNPs were additionally analyzed for association with a SCL-90-based dichotomous AG phenotype in the NBS comprising 3845 healthy participants. The minor allele of a further SNP rs7688285, was strongly associated with increased risk for the SCL-90 based dichotomous AG phenotype (P rs7688285 = 4.3 × 10 − 4 ; Table 1 ).
Analysis of the 20 examined SNPs for the categorical phenotype of PD/AG showed an overlap of significant results with both the dimensional ACQ and the dichotomous SCL-90-based AG phenotype for both genome-wide significant SNPs rs78726293 (P rs78726293 = 0.033) and rs191260602 (P rs191260602 = 0.033), as well as for rs7688285 (P = 7.6 × 10
). Again, always the minor alleles conveyed genetic risk (Table 1 ).
Functional assessment: bioinformatic, post-mortem and cell system expression analyses None of the four strongly associated SNPs could be classified as an expression quantitative trait locus in the GTEx database.
Genotype-specific differences of the promoter region risk variant rs7688285 on mRNA expression levels were found in the midbrain (N = 50; AA = 0/AG = 12/GG = 38), where the minor, risk (A)-allele increased the mean expression of GLRB (beta = 0.498; P = 0.013) significantly (Supplementary Figure 2A) . Neither in forebrain (N = 59; AA = 1/AG = 16/GG = 42; P = 0.421) nor in the (Figure 2a ) during an emotion-potentiated startle paradigm was significant in a healthy sample of no-risk allele carriers (N = 77; t(76) = 5.12, P o0.004), but not in risk allele carriers (N = 24; t(23) = 1.15, P40.60) indicating impaired startle habituation in risk allele carriers (Figure 2a) .
During a behavioral avoidance test (Figure 2b) , PD/AG patients carrying a GLRB risk allele (N = 52) exhibit increased startle responsivity during threat as reflected in stronger increases in startle potentiation from last minute of anticipation to first minute of exposure than no-risk allele carriers (N = 63; group × time F(1, 113) = 5.22, P o 0.05; η group revealed potentiated startle in both the threat (CTX+) and the safety context (CTX-) without difference between the two (t(22) = 0.11, P = 0.915), in contrast to the no-risk group that featured potentiated startle in the CTX+ only (t(52) = 2.75, P = 0.008). Accordingly, startle potentiation in the CTX-was significantly higher for risk allele carriers compared with the norisk group (t(74) = 2.50, P = 0.015). Again pointing to impaired startle habituation, we found that startle responses in CTX-declined across acquisition in the no-risk group (Acquisition1 vs Acquisition2: t(52) = 2.79, P = 0.007), but not in the risk group (t(22) = 0.24, P = 0.811). Finally, we observed no group differences during extinction, but the high-risk group showed a stronger sensitization of startle magnitudes in CTX+ during test, that is, spontaneous recovery (context x group interaction: F(1, 74) = 5.77, P = .019, η 2 p = 0.072). The resulting significantly increased startle responses in CTX+ in the risk compared with the no-risk group (t(74) = 2.78, P = 0.007) further emphasizes increased responsivity of the startle system in the risk group.
Functional assessment: fear network During late cue conditioning, GLRB risk allele carriers showed significantly stronger CS+-reactivity in several regions of interest of the fear network (thalamus, putamen/pallidum at P (FEW-corrected) ; Table 6 ) as well as stronger CS+-reactivity in skin conductance responses (stimulus x group interaction: F(1, 105) = 3.56, one-sided P = 0.031, η 2 = 0.03, Figure 3f ).
Figures 3a and b and Supplementary
In addition, GLRB risk allele carriers showed significantly stronger general CS-unspecific activation in left pre-and postcentral gyrus (Figure 3d ), the bilateral pallidum (Figure 3e ) and putamen, as well as the right thalamus during both early and late acquisition in absence of any main effects of group on skin conductance responses (F(1, 105) = 3.56, P = 0.17, η 2 = 0.02). In addition, during early acquisition GLRB risk carriers also displayed generally stronger activation in the left amygdala (Figure 3c ) than no-risk allele carriers as well as stronger bilateral insula activation during late acquisition (Supplementary Table 6 ).
Agoraphobic behavior in heterozygous Glrb knockout mice In heterozygous Glrb +/spa mice, decreased Glrb expression levels were observed both at the mRNA and protein level, in particular in thalamus and hippocampus (Supplementary Figure 3) . Interestingly, these regions were found to be differentially activated as a function of GLRB genotype in the human fear-conditioning paradigm (see above). Heterozygous Glrb +/spa mice showed a significantly enhanced agoraphobic behavior demonstrated by less time spent in the center of the open field (+/+ 0.52 ± 0.05 min; +/spa 0.4 ± 0.03 min). Both groups of animals, however, did not differ in distance traveled and number of entries into the field (Figure 4 ).
DISCUSSION
Beyond classical diagnostic phenotypes, the specification of functional dimensions of behavior as done in the Research Domain Criteria (RDoC) approach 53 aims at obtaining insights into the biological basis of mental illness. In this context, negative valence and arousal systems 54 are relevant to PD/AG. The development of PD/AG in early adulthood is preceded by Figure 3 . Fear network activation. Significant group differences at a significance threshold of pFWE SVC between GLRB risk allele carriers and no-risk allele carriers for conditioned stimuli (CS) discrimination in thalamic (a) and striatal regions (b) during the second half of fear acquisition. Group differences during early acquisition (corresponding activation pattern in late acquisition is not shown) in general CS-unspecific neural activation in the amygdala (c), pre-/post-central areas (d), as well as striatal (putamen) areas (e) and their respective peakvoxel parameter estimates (for illustrative purposes). Corresponding group differences in skin conductance response (SCR) CS discrimination between GLRB non-risk and risk allele carriers (f). Rc, range-corrected. Error bars represent s.e.m. Visualization threshold is set to Po 0.01 for illustrative purposes only. increased scores on dimensional anxiety phenotypes with negative valence such as anxiety sensitivity 55 and agoraphobic cognitions, 56 which are thus relevant proxies for PD/AG. To start with, we therefore performed a hypothesis-generating GWAS using the ACQ in a German cohort (MEGA wave 1), which suggested that allelic variation in GLRB on chromosome 4q31-34 is associated with quantitative ACQ scores. Results from a larger sample (MEGA waves 1 and 2) and two independent sample (NBS, PanicNet waves 1 and 2) supported this finding and extended it to a dichotomous AG phenotype as well as the categorical phenotype PD/AG. This chromosomal locus (4q31-34) had previously been proposed as genome-wide linkage locus for anxiety disorders. 57 In the linkage scan, the most significant marker (D4S413) is located a mere 384 kb from rs7688285 in GLRB.
On the molecular level, we found the risk allele to go along with altered GLRB expression in vitro and post mortem.
In the next step, we asked which neural mechanisms are linked to the behavioral phenotypes, along the RDoC idea. The inhibitory glycine system is more ancient than the GABA system and thus more prevalent in evolutionary older brain regions from the spinal cord to the midbrain. 58 The effects of glycine are mediated by heteromeric receptors formed by Gly alpha 1-4 and Gly beta subunits. 59 Single point mutations in the GLRB gene have recently been shown to lead to hyperekplexia 2 (OMIN #614619), a rare neurological disorder with Mendelian heritability. 60, 61 These patients suffer from exaggerated startle responses to unexpected noise or tactile stimuli. On the translational level, the phenotype is confirmed by the spastic mouse (featuring a substantial reduction of Glrb), which is characterized by an increased startle reaction. 62 Although, in humans, startle symptoms may diminish with age, (agora-) phobic behavior may become a more prominent clinical feature. 63, 64 Based on the startle phenotype of hyperekplectic patients and the observation that startle reactivity is inherited, 65, 66 we investigated functional intermediate phenotypes with a focus on startle response as possible immediate functional consequences of GLRB genetic variation. Three different samples provide converging evidence that GLRB risk SNPs result in slower habituation, stronger potentiation and generalization of startle, although subtler as compared with the-potentially more deleterious-mutations in GLRB causing hyperekplexia. These genetic modulations of defensive reactivity of brain stem reflexes during potential threat, which is mediated at a subcortical level, 56, 67 did not go along with concordant panic or anxiety ratings. Accordingly, at the level of brain function-and possibly mediated by GLRB expression changes in midbrain as suggested by our post-mortem data-GLRB risk alleles were associated not only with increased activation of the fear network, but with a generally stronger activation of sensory networks including the thalamus and post-central gyrus as well as the motor network (precentral gyrus, pallidum and putamen) suggesting a general higher reactivity independent of the presence of an aversive stimulus.
Being a very basic mechanism, the observed increased startle responses likely suggest a link between the arousal system and the negative valence system causing an increased likelihood to shy away from threats, that is, increased defensive reactivity. 53, 54 Consistent with our findings in humans and extending the known phenotype of the spastic mouse, we showed that partial Glrb knockout mice exhibited avoidance of a novel open space, a behavior we recently confirmed to be related to agoraphobic fear in humans. 3 At the mechanistic level, it is somewhat puzzling that the phenotype-associated rs7688285 A allele in fact was not found with decreased, but instead increased GLRB expression in a heterologous cell system as well as in post-mortem samples. However, an increase in GLRB expression does not necessarily result in enhanced functional pentameric glycine receptors, which are composed of both GlyRbeta and GlyR alpha subunits. An enhanced expression of GlyRbeta may, for example, result in an upregulation of the 2alpha/3beta variant, to the disadvantage of the functionally different homomeric GlyR alpha receptor, 68 and hence at the functional level may well have similar consequences as the mouse knockout phenotype. As the subunit composition of the glycine receptor changes during the life span, 69, 70 this may be particularly relevant during neural development. As such divergences between mouse knockout and human genetic variants are a common though not well understood phenomenon in psychiatric genetics (for example, for the 5HTT and NPSR1 genes), mouse models for specific human genetic variants, in our case of GRLB, are definitively needed.
There are a few limitations of our study. First, this is a study in rather homogenous proband and patient samples from Germany and the neighboring Netherlands. Thus, the generalizability to other populations remains to be elucidated. Second, the sample sizes are comparably small, especially for the PD/AG sample. Hence, further replication studies and meta-analyses, 30 for example, in the context of a psychiatric genomics consortium framework are paramount. Third, the associated polymorphisms differed between samples. This may, however, simply be due to the different phenotypes studied with greater power of the dimensional sample for rare polymorphisms with bigger effect sizes and greater power of the dichotomous sample for the more common polymorphisms. Nevertheless, the ultimate phenotype PD/AG demonstrated significant associations for both types of polymorphisms. Fourth, the human intermediate phenotype paradigms were not specifically designed to examine GLRB gene effects on startle responses. The proximity of the startle reaction to the hyperekplexia phenotype in our opinion, however, is close enough to overcome this shortcoming. Fifth, the definition of the risk population in the intermediate phenotype paradigms is based on a combination of significant alleles, as sample sizes precluded gene-based analyses as well as investigating the effects of individual rare variants on their own. Reverse-phenotyping studies, which are designed to specifically test a potential influence of specific GLRB variants on intermediate phenotypes in larger samples are needed. Deep sequencing of the GLRB gene for rare variants in larger samples of patients as compared with healthy probands with calculation of a polyallelic risk score will help to clarify this issue. 71 In summary, our findings provide evidence that GLRB allelic variation may contribute not only to the rare severe neurological disorder hyperekplexia, but also to the risk of the comparably milder categorical anxiety disorder PD/AG by increasing startle response and, as a result, agoraphobic cognitions. Our data point to the startle reflex being one pathomechanism in PD/AG. Within the RDoC matrix, this places GLRB in the arousal gene list, whereas adding PD/AG to the clinical entities linked to this domain. As GLRB can be subjected to pharmacological interventions, its modulation may comprise a novel therapeutic option in PD/AG.
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